122 related articles for article (PubMed ID: 25089601)
1. Malignant melanoma in teenagers and young adults.
Kolandijan NA; Wei C; Burke A; Bedikian AY
J Pediatr Hematol Oncol; 2014 Oct; 36(7):552-8. PubMed ID: 25089601
[TBL] [Abstract][Full Text] [Related]
2. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.
Keilholz U; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; Thomas J; Proebstle TM; Schmittel A; Schadendorf D; Velu T; Negrier S; Kleeberg U; Lehman F; Suciu S; Eggermont AM
J Clin Oncol; 2005 Sep; 23(27):6747-55. PubMed ID: 16170182
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma.
Bedikian AY; Johnson MM; Warneke CL; Papadopoulos NE; Kim K; Hwu WJ; McIntyre S; Hwu P
Cancer Invest; 2008 Jul; 26(6):624-33. PubMed ID: 18584354
[TBL] [Abstract][Full Text] [Related]
5. Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival?
Bedikian AY; Johnson MM; Warneke CL; Papadopoulos NE; Kim KB; Hwu WJ; McIntyre S; Rohlfs M; Homsi J; Hwu P
Melanoma Res; 2011 Feb; 21(1):84-90. PubMed ID: 21102360
[TBL] [Abstract][Full Text] [Related]
6. Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database.
Khan MA; Andrews S; Ismail-Khan R; Munster PN; Brem S; King J; Reintgen DS; Sondak VK; Daud AI
Cancer Control; 2006 Jul; 13(3):211-7. PubMed ID: 16885917
[TBL] [Abstract][Full Text] [Related]
7. Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma.
Zogakis TG; Bartlett DL; Libutti SK; Liewehr DJ; Steinberg SM; Fraker DL; Alexander HR
Ann Surg Oncol; 2001 Dec; 8(10):771-8. PubMed ID: 11776490
[TBL] [Abstract][Full Text] [Related]
8. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
Bedikian AY; Johnson MM; Warneke CL; McIntyre S; Papadopoulos N; Hwu WJ; Kim K; Hwu P
J Immunotoxicol; 2008 Apr; 5(2):201-7. PubMed ID: 18569391
[TBL] [Abstract][Full Text] [Related]
9. Is sex an independent prognostic factor in cutaneous head and neck melanoma?
Arce PM; Camilon PR; Stokes WA; Nguyen SA; Lentsch EJ
Laryngoscope; 2014 Jun; 124(6):1363-7. PubMed ID: 24122966
[TBL] [Abstract][Full Text] [Related]
10. [Adjuvant chemotherapy in the combined treatment of primary circumscribed malignant melanoma of the skin].
Korovin SI
Lik Sprava; 1998 May; (3):114-7. PubMed ID: 9695586
[TBL] [Abstract][Full Text] [Related]
11. Metastatic melanoma: a regional review and future directions.
Khan KH; Goody RB; Hameed H; Jalil A; Coyle VM; McAleer JJ
Tumori; 2012; 98(5):575-80. PubMed ID: 23235751
[TBL] [Abstract][Full Text] [Related]
12. Biochemotherapy for melanoma: rational therapeutics in the search for weapons of melanoma destruction.
Margolin KA
Cancer; 2004 Aug; 101(3):435-8. PubMed ID: 15274056
[No Abstract] [Full Text] [Related]
13. Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study.
Qian DC; Kleber T; Brammer B; Xu KM; Switchenko JM; Janopaul-Naylor JR; Zhong J; Yushak ML; Harvey RD; Paulos CM; Lawson DH; Khan MK; Kudchadkar RR; Buchwald ZS
Lancet Oncol; 2021 Dec; 22(12):1777-1786. PubMed ID: 34780711
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
[TBL] [Abstract][Full Text] [Related]
15. High-dose interleukin-2 and interferon as first-line immunotherapy for metastatic melanoma: long-term follow-up in a large unselected Danish patient cohort.
Bastholt L; Svane IM; Bjerregaard JK; Herrstedt J; Hróbjartsson A; Schmidt H
Eur J Cancer; 2019 Jul; 115():61-67. PubMed ID: 31108244
[TBL] [Abstract][Full Text] [Related]
16. Age has no significant impact on overall survival and on treatment tolerability in relapsed stage IV cutaneous malignant melanoma patients receiving Cisplatin, Gemcitabine, and Treosulfan.
Atzpodien J; Terfloth K; Fluck M; Reitz M
Am J Clin Oncol; 2011 Feb; 34(1):2-5. PubMed ID: 20042970
[TBL] [Abstract][Full Text] [Related]
17. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma.
Agarwala SS; Glaspy J; O'Day SJ; Mitchell M; Gutheil J; Whitman E; Gonzalez R; Hersh E; Feun L; Belt R; Meyskens F; Hellstrand K; Wood D; Kirkwood JM; Gehlsen KR; Naredi P
J Clin Oncol; 2002 Jan; 20(1):125-33. PubMed ID: 11773161
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy and chemoimmunotherapy for metastatic malignant melanoma: review and recent advances.
Khayat D; Coeffic D
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():238-47. PubMed ID: 10895160
[No Abstract] [Full Text] [Related]
19. Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma.
Harcharik S; Bernardo S; Moskalenko M; Pan M; Sivendran M; Bell H; Hall LD; Castillo-MartÃn M; Fox K; Cordon-Cardo C; Chang R; Sivendran S; Phelps RG; Saenger Y
J Am Acad Dermatol; 2014 Jun; 70(6):1036-44. PubMed ID: 24698703
[TBL] [Abstract][Full Text] [Related]
20. Pathologic complete response to intralesional interleukin-2 therapy associated with improved survival in melanoma patients with in-transit disease.
Hassan S; Petrella TM; Zhang T; Kamel-Reid S; Nordio F; Baccarelli A; Sade S; Naert K; Habeeb AA; Ghazarian D; Wright FC
Ann Surg Oncol; 2015; 22(6):1950-8. PubMed ID: 25366584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]